A Phase III, Randomised, Open, Controlled, Multicentre, Primary Vaccination Study To Evaluate The Immunogenicity And Persistence Of 1 And 2 Doses Of Meningococcal Conjugate Vaccine MenACWY-TT In Toddlers (After 1 Month And Up To 5 Years) And To Demonstrate Non-inferiority Of Co-administration Of MenACWY-TT And 13-valent Pneumococcal Conjugate Vaccine Prevenar 13(Registered) Versus Separate Administration Of The 2 Vaccines

Trial Profile

A Phase III, Randomised, Open, Controlled, Multicentre, Primary Vaccination Study To Evaluate The Immunogenicity And Persistence Of 1 And 2 Doses Of Meningococcal Conjugate Vaccine MenACWY-TT In Toddlers (After 1 Month And Up To 5 Years) And To Demonstrate Non-inferiority Of Co-administration Of MenACWY-TT And 13-valent Pneumococcal Conjugate Vaccine Prevenar 13(Registered) Versus Separate Administration Of The 2 Vaccines

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Meningococcal infections; Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Acronyms MENACWY-TT-104
  • Sponsors GlaxoSmithKline; Pfizer
  • Most Recent Events

    • 14 Sep 2017 Planned End Date changed from 18 Feb 2020 to 12 Feb 2020.
    • 14 Sep 2017 Planned primary completion date changed from 18 Feb 2020 to 12 Feb 2020.
    • 21 Mar 2017 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top